S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought

Cano Health (CANO) Price Target & Analyst Ratings

$0.41
-1.11 (-73.00%)
(As of 08/11/2023 08:48 PM ET)
Compare
Today's Range
$0.38
$0.80
50-Day Range
$0.41
$1.73
52-Week Range
$0.38
$9.75
Volume
91.50 million shs
Average Volume
6.59 million shs
Market Capitalization
$220.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.69

Cano Health Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Reduce
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$2.69
556.37% Upside
High Prediction$7.00
Average Prediction$2.69
Low Prediction$0.80
TypeCurrent
8/14/22 to 8/14/23
1 Month Ago
7/15/22 to 7/15/23
3 Months Ago
5/16/22 to 5/16/23
1 Year Ago
8/14/21 to 8/14/22
Consensus Rating
Reduce
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
7 Buy rating(s)
Hold
9 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$2.69$3.09$3.64$10.80
Predicted Upside556.37% Upside21.93% Upside35.81% Upside51.02% Upside
Get Cano Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CANO and its competitors with MarketBeat's FREE daily newsletter.


CANO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CANO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cano Health Stock vs. The Competition

TypeCano HealthMedical CompaniesS&P 500
Consensus Rating Score
1.90
2.65
2.48
Consensus RatingReduceModerate BuyHold
Predicted Upside556.37% Upside3,392.97% Upside324.28% Upside
News Sentiment RatingNegative News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/11/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$4.00 ➝ $0.80-47.54%
5/16/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$1.00-21.26%
1/6/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$12.00 ➝ $1.25+13.64%
1/5/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
12/13/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderperform$1.50+6.38%
11/28/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$4.00+136.69%
11/10/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$10.00 ➝ $3.00+35.13%
11/10/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Ransom
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
9/7/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$7.00+19.05%
(Data available from 8/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CANO Price Target - Frequently Asked Questions

What is Cano Health's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Cano Health stock is Reduce based on the current 1 sell rating and 9 hold ratings for CANO. The average twelve-month price prediction for Cano Health is $2.69 with a high price target of $7.00 and a low price target of $0.80. Learn more on CANO's analyst rating history.

Do Wall Street analysts like Cano Health more than its competitors?

Analysts like Cano Health less than other Medical companies. The consensus rating for Cano Health is Reduce while the average consensus rating for medical companies is Moderate Buy. Learn more on how CANO compares to other companies.

Is Cano Health being downgraded by Wall Street analysts?

Over the previous 90 days, Cano Health's stock had 2 downgrades by analysts.

Does Cano Health's stock price have much upside?

According to analysts, Cano Health's stock has a predicted upside of 7.09% based on their 12-month price targets.

What analysts cover Cano Health?

Cano Health has been rated by Citigroup, Jefferies Financial Group, and Piper Sandler in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:CANO) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -